Gauthier G, Martins da Silva A
Eur Neurol. 1982;21(4):217-26. doi: 10.1159/000115484.
Bromocriptine (Parlodel) was given for 2 years to 17 parkinsonian patients showing inadequate response to treatment over a mean of 7 years with levodopa combined with a decarboxylase inhibitor. 11 of the patients had developed dyskinesia and 13 the on-off phenomenon during levodopa therapy. When the dose of bromocriptine reached 30 mg daily, after 4 weeks' treatment, a highly significant improvement (p less than 0.001) was observed in the following six variables: bradykinesia, rigidity, tremor, feeding, dressing and speech. These improvements have now been maintained for 2 years. The on-off phenomenon disappeared in 9 out of 13 patients. Side effects were mild and transient. Involuntary movements existing prior to bromocriptine administration were improved by reducing the dose of levodopa. The mean daily dose--after progressive and individual adjustment--was 46 mg bromocriptine combined with 435 mg levodopa plus decarboxylase inhibitor.
对17名帕金森病患者给予溴隐亭（ Parlodel ）治疗2年，这些患者在平均7年的时间里接受左旋多巴与脱羧酶抑制剂联合治疗，疗效欠佳。11名患者在左旋多巴治疗期间出现了运动障碍，13名患者出现了开关现象。当溴隐亭剂量达到每日30毫克，治疗4周后，在以下六个变量上观察到高度显著的改善（ p小于0.001 ）：运动迟缓、强直、震颤、进食、穿衣和言语。这些改善目前已持续了2年。13名患者中有9名的开关现象消失。副作用轻微且短暂。通过减少左旋多巴剂量，溴隐亭给药前就存在的不自主运动得到了改善。经过逐步个体化调整后，平均每日剂量为46毫克溴隐亭加435毫克左旋多巴及脱羧酶抑制剂。
